AUA Congress 2021
AUA 2021 Prostate Cancer
- AUA 2021: Impact of the COVID Pandemic on the Diagnosis and Treatment of Urologic Cancers
- AUA 2021: Masitinib Plus Docetaxel as First-Line Treatment of Metastatic Castrate Refractory Prostate Cancer: Results from Study AB12003
- AUA 2021: A High Through-Put Test Interrogating 442 Small Non-Coding RNAs Extracted from Urine Exosomes Accurately Identifies and Stratifies Prostate Cancer into Low-, Intermediate- or High-Risk Disease
- AUA 2021: Prospective Evaluation of 18F-DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer: Analysis of 18F-DCFPyL Uptake in Possible Extra-Pelvic Oligometastases
- AUA 2021: Prospective Study of 68Ga-RM2 PET/MRI in Patients With Biochemically Recurrent Prostate Cancer and Negative Conventional Imaging
AUA 2021 Bladder Cancer
- AUA 2021: Utility of Blue Light Flexible Cystoscopy for Bladder Cancer Surveillance after Intravesical Therapy
- AUA 2021: Intravesical Therapy in Patients with Intermediate-Risk Non-Muscle-Invasive Bladder Cancer: A Systematic Review and Network Meta-Analysis of Oncologic Outcomes
- AUA 2021: Pre-Surgical Multiparametric Magnetic Resonance Imaging Features Predicting Continence After Robotic Radical Cystectomy With Orthotopic Bladder Reconstruction: Preliminary Findings Form PURE-01 Trial
- AUA 2021: Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma in the JAVELIN Bladder 100 Trial: Subgroup Analysis by Duration of Treatment-Free Interval from End of Chemotherapy to Start of Maintenance
- AUA 2021: Long-Term Recurrence Free Survival Following UGN-101 Treatment for Low-Grade Upper Tract Urothelial Carcinoma
AUA 2021 Kidney Cancer
- AUA 2021: NAXIVA - A Phase II Neoadjuvant Study of Axitinib for Reducing Extent of Venous Tumor Thrombus in Clear Cell Renal Cell Cancer with Venous Invasion: Translational Results
- AUA 2021: A Multicenter Assessment of Survival in Patients with Metastatic Renal Cell Carcinoma (mRCC) Who Received Immune Checkpoint Inhibitor Therapy (ICI) with or without Cytoreductive Nephrectomy (CN)
AUA 2021 Testicular and Penile Cancer
AUA 2021 OAB and Lower Urinary Tract Infections
AUA 2021 Press Releases
- ImmunityBio Announces Positive Durable Responses in BCG Unresponsive Bladder Cancer Patients with a Complete Response Rate of 72%, Median Duration of Complete Response of 19.9 Months, and 85% Remaining Cystectomy-free in Phase 2/3 Trial
- Urovant Sciences Presents Positive Ambulatory Blood Pressure Data Showing That GEMTESA® (vibegron) 75 mg in Overactive Bladder Was Not Associated with Statistically Significant or Clinically Meaningful Effects on Blood Pressure or Heart Rate
- ERLEADA® (apalutamide) Oral Presentations Demonstrate Importance of Prostate Specific Antigen (PSA) as Key Efficacy Indicator and Show Strong Patient Adherence Rates
- Dr. J. Curtis Nickel Urinary Microbiome Study Using MicroGenDX NGS Indicates Microbial Diversity Varies by Age and Gender
- Janssen to Showcase Commitment to Advancing Science for Genitourinary Cancers at AUA 2021
